AIDS

AIDS is a leading journal that showcases pioneering research and significant findings related to HIV and AIDS. It features well-researched articles that cover various aspects of scientific, clinical, epidemiological, and social studies. The journal particularly encourages submissions that delve into fundamental science, community-focused research, implementation strategies, and clinical trials that enhance understanding in the field. The published works include Original Papers, Brief Communications, Field Notes, Research Letters, and Correspondence, along with invited pieces like Editorial Reviews, Opinion Articles, Viewpoints, Editorial Comments, and Fast Track publications. The Fast Track option allows for the quick publication of original short articles that contain crucial and time-sensitive data.

International, Trade/B2B

English

Journal

Outlet metrics

Domain Authority

Ranking

Global

N/A

Country

N/A

Articles

Tolebrutinib Slows Disability Progression in MS, but Elevated Liver Enzymes Need to be Monitored : Neurology Today

2 weeks ago | journals.lww.com | Dawn Fallik

Tolebrutinib, a brain-penetrant Bruton tyrosine (BTK) inhibitor, significantly slowed disability progression in multiple sclerosis, according to research from two different phase 3 trials presented at the AAN Annual Meeting in San Diego.
Over-the-Counter Analgesics Improve Symptoms, Recovery Time After Concussion : Neurology Today

3 weeks ago | journals.lww.com | Gina Shaw

Use of over-the-counter (OTC) analgesics—including both acetaminophen and non-steroidal anti-inflammatory drugs (NSAIDs)—after a traumatic brain injury (TBI) was significantly associated with improved concussion symptoms and recovery, according to new data presented at the AAN Annual Meeting in San Diego. The prospective cohort study of National Collegiate Athletic Association (NCAA) and military cadets also found that the OTC drugs led to a quicker return to play.
Large Study Confirms Modern Hormonal Contraceptives Not Associated with Vascular Risk in Women With Migraine : Neurology Today

3 weeks ago | journals.lww.com | Gina Shaw

Modern hormonal contraceptives, which contain substantially lower doses of estrogen compared with earlier-generation high-dose combined oral contraceptives, are not associated with an increased risk of stroke and other vascular events in women with migraine, both with and without aura, according to findings presented at the AAN Annual Meeting in San Diego. The large study used data from a nationwide de-identified electronic health record database.
Inebilizumab Improves Myasthenia Gravis Severity, Reduces Steroid Dependency : Neurology Today

3 weeks ago | journals.lww.com | Gina Shaw

Inebilizumab (Uplizna), a monoclonal antibody targeting CD19+ B-cells, significantly improves disease severity in patients with generalized myasthenia gravis (MG), according to new findings from the MINT phase 3 clinical trial presented at the AAN Annual Meeting in San Diego.
Fremanezumab Outperforms Placebo for Migraine Prevention in Pediatric, Adolescent Population : Neurology Today

3 weeks ago | journals.lww.com | Gina Shaw

Fremanezumab (Ajovy)—a calcitonin gene-related peptide agonist (CGRP)— is safe and effective for prevention of episodic migraine in children and adolescents as young as 6 years old, according to findings presented at the AAN 2025 Annual Meeting in San Diego, The multicenter, double-blind, parallel-group, phase 3 study—led by headache medicine specialist and child neurologist Andrew Hersey, MD, PhD, FAAN, endowed chair and director of the division of neurology at Cincinnati Children's...
Will Oral Therapies for Neurogenetic Disorders Change the Pl... : Neurology Today

3 weeks ago | journals.lww.com | Gina Shaw

Article In BriefA new approval for an oral therapy for a disease-modifying therapy for spinal muscular atrophy elicited discussion about whether oral therapies have changed the treatment landscape for neurogenetic disorders. Experts said the answer varies depending on the therapy and condition. The US Food and Drug Administration (FDA) has approved a new tablet form of Genentech's spinal muscular atrophy (SMA) treatment risdiplam (Evrysdi) for patients ages 2 and older.
How Neurology Practices Are Integrating Multidisciplinary Pr... : Neurology Today

3 weeks ago | journals.lww.com | Lola Butcher

Article In BriefAs the needs of neurology patients have become increasingly complex, many neurology clinics now include an array of multidisciplinary services and specialists. The clinics provide a boost to patient care by providing the array of services under one department. Multidisciplinary clinics, long used to care for patients with high-disability neurologic conditions, are increasingly being developed to improve patient care for other groups of patients.
Anti-DEI Efforts Put Neurology Research, Workforce Programs ... : Neurology Today

3 weeks ago | journals.lww.com | Gina Shaw

Article In BriefIn February, researchers conducting research involving diverse, underrepresented populations received notices from various NIH agencies that their grants had been cancelled or cut. Leaders in the field of diversity, equity, inclusion (DEI) discuss the downstream effect of these cuts and the commitment of the AAN to promoting DEI in research and recruitment.
Exposure to Wildfire Smoke Linked to Increased Risk of Demen... : Neurology Today

3 weeks ago | journals.lww.com | Dan Hurley

Article In BriefA new study found that people younger than 75 years old had a 73 percent increase in the risk of developing dementia for each additional microgram per cubic meter exposure to wildfire smoke. The study author urged neurologists in wildfire-prone areas to educate their patients about the need to minimize time outside in smoky conditions, to wear a fitted N-95 or KN95 mask, and to have an air filtration system in their home.
Repeat Expansions Significantly Raise Risk of Alzheimer's, T... : Neurology Today

3 weeks ago | journals.lww.com | Dan Hurley

Article In BriefTwo new papers found the greater number of repeat expansions within the CASP8 gene produced toxic aggregates called polyGlycineArginine proteins, which were associated with an increased risk of Alzheimer's disease. Independent experts said that if these findings are confirmed in other research papers, clinicians will need to look for more of these expansions.